GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » Cyclically Adjusted PS Ratio

Chimerix (STU:CXF) Cyclically Adjusted PS Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Chimerix Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Chimerix's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Cyclically Adjusted PS Ratio Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 11.16 9.62 -

Chimerix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.73 - - - -

Competitive Comparison of Chimerix's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Chimerix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Chimerix's Cyclically Adjusted PS Ratio falls into.



Chimerix Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Chimerix's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Chimerix's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Chimerix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.022 100.560 0.029
201409 0.026 100.428 0.034
201412 0.024 99.070 0.032
201503 0.028 99.621 0.037
201506 0.088 100.684 0.115
201509 0.044 100.392 0.058
201512 0.062 99.792 0.082
201603 0.024 100.470 0.031
201606 0.035 101.688 0.045
201609 0.013 101.861 0.017
201612 0.040 101.863 0.052
201703 0.022 102.862 0.028
201706 0.013 103.349 0.017
201709 0.016 104.136 0.020
201712 0.033 104.011 0.042
201803 0.013 105.290 0.016
201806 0.021 106.317 0.026
201809 0.007 106.507 0.009
201812 0.084 105.998 0.104
201903 0.041 107.251 0.050
201906 0.025 108.070 0.030
201909 0.030 108.329 0.036
201912 0.099 108.420 0.120
202003 0.018 108.902 0.022
202006 0.020 108.767 0.024
202009 0.022 109.815 0.026
202012 0.015 109.897 0.018
202103 0.015 111.754 0.018
202106 0.004 114.631 0.005
202109 0.001 115.734 0.001
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.005 125.017 0.005
202209 0.374 125.227 0.394
202212 0.009 125.222 0.009
202303 0.003 127.348 0.003
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chimerix  (STU:CXF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Chimerix Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Chimerix's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (STU:CXF) Business Description

Industry
Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Chimerix (STU:CXF) Headlines

No Headlines